Abstract | BACKGROUND: AIMS:
Sulindac was given to patients with sporadic colorectal adenomatous polyps to evaluate its effects on them, and histological analysis was performed to elucidate the mechanism of the polyp regression, as well the kind of adenomatous polys that are susceptible to the agent. SUBJECTS: METHODS:
Sulindac (300 mg daily) was given for four months, followed by colonoscopy with removal of the residual polyps. Polyp size, degree of atypia, inflammatory cell infiltration in the polyps, and immunostaining for mutant p53 product were evaluated before and after treatment. RESULTS: 13 of the 20 polyps shrank or disappeared. Patient sex, polyp location, size, degree of atypia, or p53 mutation did not affect the response, but polyps in older patients were more sensitive to sulindac. The degree of atypia or inflammatory cell infiltration was not affected by the treatment. A polyp containing a focal cancer was unresponsive. CONCLUSIONS:
|
Authors | N Matsuhashi, A Nakajima, Y Fukushima, Y Yazaki, T Oka |
Journal | Gut
(Gut)
Vol. 40
Issue 3
Pg. 344-9
(Mar 1997)
ISSN: 0017-5749 [Print] England |
PMID | 9135523
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Tumor Suppressor Protein p53
- Sulindac
|
Topics |
- Adenomatous Polyps
(drug therapy, metabolism, pathology)
- Aged
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Colorectal Neoplasms
(drug therapy, metabolism, pathology)
- Female
- Humans
- Immunohistochemistry
- Male
- Middle Aged
- Mutation
- Sulindac
(therapeutic use)
- Tumor Suppressor Protein p53
(analysis, genetics)
|